

S/N 10/580,169

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Christoph Binkert et al.	Examiner:	Laura Lynne Stockton
Serial No.:	10/580,169	Group Art Unit:	1626
Filed:	Dec. 1, 2006	Docket No.:	AC-44-US
Title:	NOVEL THIAZOLIDIN-4-ONE DERIVATIVES	Patent No.	7,435,828


REQUEST FOR A CERTIFICATE OF CORRECTION

PURSUANT TO 37 C.F.R. §§ 1.322 and 1.323


Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The above-referenced issued U.S. Patent No. 7,435,828 contains a number of chemical structural errors incurred through the fault of the U.S. Patent Office. Some of the structures do not correspond to those in the specification originally submitted. Therefore, please correct the following:


Column 41, about lines 5-12, column 43, about lines 5-10, and column 45, about lines 5-10, replace:




Column 45, about lines 35-40, example 25, replace:




with




Column 47, about lines 10-15, and column 49, about lines 5-10, replace:




with




Column 50, about lines 40-45, and Column 51, about lines 5-10, replace:




with




Column 53, about lines 5-10, and column 55, about lines 5-10, replace:




with




Column 55, about lines 15-25, Example 43, replace:




with




Column 55, about lines 55-60, Example 47, replace:




with




Column 58, about lines 15-20, replace:




with




Column 77, about lines 40-45, Example 86, replace:




with




Column 83, about lines 7-13, replace:




with




Column 83, about lines 47-55 and column 85, about lines 5-10, replace:




with




Column 87, about lines 5-10, replace:




with




Column 88, about lines 45-50, and column 89, about lines 5-10, replace:




with




Column 91, about lines 15-20, replace:




with




Column 104, about lines 45-55 and column 105, about lines 5-15, replace:




with




Column 105, about lines 47-55 and column 106, about lines 5-10, replace:




with




Column 106, about lines 45-50 and column 107, about lines 5-15, replace:




with




Column 106, about lines 60-65, Example 149, replace:




with




Column 107, about lines 20-25, Example 150, replace:




with




Column 107, about lines 50-55 and column 108, about lines 5-10, replace:




with



Column 108, about lines 40-45, Example 154, replace:



Column 108, about lines 50-55, Example 155, replace:



In addition to the corrections above, Applicants also inadvertently submitted page 79 of the specification during national phase entry, which page 79 was not transmitted during the PCT stage. This mistake occurred through error and without any deceptive intent. Therefore, Applicants request page 79 of the specification originally submitted, or the entire Column 97 and Column 98, up to line 39 of the publication number 7,435,828 to be deleted.

37 C.F.R. § 1.322(b) provides that “[i]f the nature of the mistake on the part of the Office is such that a certificate of correction is deemed inappropriate in form, the Director may issue a corrected patent in lieu thereof as a more appropriate form for certificate of correction, without expense to the patentee”. Due to the large number of errors in the structures throughout the issued patent, Applicants respectfully request for a corrected patent in lieu of the certificate of correction. Should a corrected patent be issued, Applicants further note typographical mistakes in column 113, line 11 (“dimethyl” should replace “d methyl”), column 113, line 26 (“phenyl” should replace “phenyi”) and column 114, line 28 (“thiazol” should replace “thiazoi”).

Therefore:

“-3-(2,3-d methyl- phenyl)-2-([Z]-isopropylimino)-thia-” should be replaced with “-3-(2,3-dimethyl- phenyl)-2-([Z]-isopropylimino)-thia-” in column 113, line 11;


“pylimino)-3-(2-methoxy- phenyl)-thiazolidin-4-one,” should replace “pylimino)-3-(2-methoxy- phenyl)-thiazolidin-4-one,” in column 113, line 26;

“3-dimethyl-phenyl)-2-([Z]-isopropylimino)-thiazol” should replace “3-dimethyl-phenyl)-2-([Z]-isopropylimino)-thiazol” in column 114, line 28.

Applicants submit herewith a fee of \$100 as required by 37 C.F.R. § 1.323. It is believed no other fees are required. Should this be incorrect, the Commissioner is authorized to charge any additional fees, or credit any overpayment, to deposit account No. 50-4255.

Respectfully submitted,

Date Jan 18, 2011



Brittany La
Reg. No. 58,337

Hoxie & Associates LLC
75 Main Street, Suite 301
Millburn, NJ 07041
973-912-5232 phone
973-912-5236 fax